Whereas, Several generic medications in 2019, especially Angiotensin-receptive Blockers (ARBs), were found in many pills to contain a cancer-causing agent, nitrosamine; and

Whereas, In the United States, the trade name drugs as well as many generics are manufactured in highly regulated facilities and are in American pharmacies; and

Whereas, Many generics that are obtained by pharmacists for patients come from generic drug purchasing and distribution agents or online and are often manufactured in foreign countries such as China, India, or third world countries where there is little or no regulation, and this appears to have occurred with the ARBs; and

Whereas, Studies show that exposure over time to these cancer-causing contaminants could cause irreparable harm; and

Whereas, It is imperative that patients when purchasing their medications have clear knowledge and transparency of where the pills were manufactured to decide if they want to buy them; therefore be it

RESOLVED, That our American Medical Association advocate to Congress to support national legislation to make it a requirement that the identity of the manufacturer(s) and the country (countries) of origin of the components of prescription medications be included on the label of the container dispensed to a patient, including generic medications. (Directive to Take Action)